Circulating plasma micro RNAs in patients with major depressive disorder treated with antidepressants: A pilot study

Psychiatry Investigation

Volumn 13, Issue 5, 2016, Pages 549-557

  Enatescu, Virgil Radu ^a,b   Papava, Ion ^a,b   Enatescu, Ileana ^a   Antonescu, Mirela ^a   Anghel, Andrei ^a   Seclaman, Edward ^a   Sirbu, Ioan Ovidiu ^a   Marian, Catalin ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Clinical Emergency County Hospital Pius Brinzeu Timisoara   (Romania)

Author keywords

Antidepressants; Major depressive disorder; Micro RNA

Indexed keywords

ANTIDEPRESSANT AGENT; MICRORNA; MICRORNA 146A 5P; MICRORNA 146B 5P; MICRORNA 221 3P; MICRORNA 24 3P; MICRORNA 26A 5P; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DOWN REGULATION; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIDDLE AGED; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SCORING SYSTEM; UPREGULATION;

EID: 84991447803     PISSN: 17383684     EISSN: 19763026     Source Type: Journal    
DOI: 10.4306/pi.2016.13.5.549     Document Type: Article

References (52)

1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593-602.
2. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-1504.
3. Laursen TM, Munk-Olsen T, Nordentoft M, Bo Mortensen P. A comparison of selected risk factors for unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia from a danish population-based cohort. J Clin Psychiatry 2007;68:1673-1681.
4. Thase ME, Ninan PT, Musgnung JJ, Trivedi MH. Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study. Prim Care Companion CNS Disord 2011;13:PCC.10m00979.
5. Ota KT, Duman RS. Environmental and pharmacological modulations of cellular plasticity: role in the pathophysiology and treatment of depression. Neurobiol Dis 2013;57:28-37.
6. Aganova EA, Uranova NA. Morphometric analysis of synaptic contacts in the anterior limbic cortex in the endogenous psychoses. Neurosci Behav Physiol 1992;22:59-65.
7. Dolan RJ, Bench CJ, Liddle PF, Friston KJ, Frith CD, Grasby PM, et al. Dorsolateral prefrontal cortex dysfunction in the major psychoses; symptom or disease specificity? J Neurol Neurosurg Psychiatry 1993;56: 1290-1294.
8. Drevets WC, Ongur D, Price JL. Reduced glucose metabolism in the subgenual prefrontal cortex in unipolar depression. Mol Psychiatry 1998;3:190-191.
9. Andreasen NC. Linking mind and brain in the study of mental illnesses: a project for a scientific psychopathology. Science 1997;275:1586-1593.
10. Honer WG. Assessing the machinery of mind: synapses in neuropsychiatric disorders. J Psychiatry Neurosci 1999;24:116-121.
11. Toni N, Buchs PA, Nikonenko I, Bron CR, Muller D. LTP promotes formation of multiple spine synapses between a single axon terminal and a dendrite. Nature 1999;402:421-425.
12. Hajsza T, MacLusky NJ, Leranth C. Short-term treatment with the antidepressant fluoxetine triggers pyramidal dendritic spine synapse formation in rat hippocampus. Eur J Neurosci 2005;21:1299-1303.
13. McEwen BS. Effects of adverse experiences for brain structure and function. Biol Psychiatry 2000;48:721-731.
14. Sheline YI. 3D MRI studies of neuroanatomic changes in unipolar major depression: the role of stress and medical comorbidity. Biol Psychiatry 2000;48:791-800.
15. Sala M, Perez J, Soloff P, Ucelli di Nemi S, Caverzasi E, Soares JC, et al. Stress and hippocampal abnormalities in psychiatric disorders. Eur Neuropsychopharmacol 2004;14:393-405.
16. Rajkowska G, Miguel-Hidalgo JJ. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets 2007;6:219-233.
17. Stefani G, Slack FJ. Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol 2008;9:219-230.
18. Serafini G, Pompili M, Hansen KF, Obrietan K, Dwivedi Y, Shomron N, et al. The involvement of microRNAs in major depression, suicidal behavior, and related disorders: a focus on miR-185 and miR-491-3p. Cell Mol Neurobiol 2014;34:17-30.
19. Barry G. Integrating the roles of long and small non-coding RNA in brain function and disease. Mol Psychiatry 2014;19:410-416.
20. Adlakha YK, Saini N. Brain microRNAs and insights into biological functions and therapeutic potential of brain enriched miRNA-128. Mol Cancer 2014;13:33.
21. Dwivedi Y. Emerging role of microRNAs in major depressive disorder: diagnosis and therapeutic implications. Dialogues Clin Neurosci 2014; 16:43-61.
22. Im HI, Kenny PJ. MicroRNAs in neuronal function and dysfunction. Trends Neurosci 2012;35:325-334.
23. Malphettes L, Fussenegger M. Impact of RNA interference on gene networks. Metab Eng 2006;8:672-683.
24. Smalheiser NR, Lugli G, Rizavi HS, Torvik VI, Turecki G, Dwivedi Y. MicroRNA expression is down-regulated and reorganized in prefrontal cortex of depressed suicide subjects. PLoS One 2012;7:e33201.
25. Lopez JP, Lim R, Cruceanu C, Crapper L, Fasano C, Labonte B, et al. miR-1202 is a primate-specific and brain-enriched microRNA involved in major depression and antidepressant treatment. Nat Med 2014;20: 764-768.
26. Baudry A, Mouillet-Richard S, Schneider B, Launay JM, Kellermann O. miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science 2010;329:1537-1541.
27. O’Connor RM, Grenham S, Dinan TG, Cryan JF. microRNAs as novel antidepressant targets: converging effects of ketamine and electroconvulsive shock therapy in the rat hippocampus. Int J Neuropsychopharmacol 2013;16:1885-1892.
28. Witwer KW. Circulating MicroRNA Biomarker Studies: Pitfalls and Potential Solutions. Clin Chem 2015;61:56-63.
29. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010;56:1733-1741.
30. Fan HM, Sun XY, Guo W, Zhong AF, Niu W, Zhao L, et al. Differential expression of microRNA in peripheral blood mononuclear cells as specific biomarker for major depressive disorder patients. J Psychiatr Res 2014;59:45-52.
31. Wan Y, Liu Y, Wang X, Wu J, Liu K, Zhou J, et al. Identification of differential microRNAs in cerebrospinal fluid and serum of patients with major depressive disorder. PLoS One 2015;10:e0121975.
32. Belzeaux R, Bergon A, Jeanjean V, Loriod B, Formisano-Treziny C, Verrier L, et al. Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transl Psychiatry 2012;2:e185.
33. Bocchio-Chiavetto L, Maffioletti E, Bettinsoli P, Giovannini C, Bignotti S, Tardito D, et al. Blood microRNA changes in depressed patients during antidepressant treatment. Eur Neuropsychopharmacol 2013;23: 602-611.
34. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Ed, Text Revision. Washington DC: American Psychiatric Association; 2000.
35. First MB, Spitzer RL, Gibon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research version (SCID-I RV). New York: Biometrics Research; 2002.
36. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296.
37. Lam RW, Michalak EE, Swinson RP. Assessment Scales in Depression, Mania and Anxiety. London, UK: Taylor and Francis; 2005.
38. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010;50:298-301.
39. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk-database: prediction of possible miRNA binding sites by “walking” the genes of 3 genomes. J Biomed Inform 2011;44:839-847.
40. Smalheiser NR, Lugli G, Rizavi HS, Torvik VI, Turecki G, Dwivedi Y. MicroRNA expression is down-regulated and reorganized in prefrontal cortex of depressed suicide subjects. PLoS One 2012;7:e33201.
41. Zhou R, Yuan P, Wang Y, Hunsberger JG, Elkahloun A, Wei Y, et al. Evidence for selective microRNAs and their effectors as common longterm targets for the actions of mood stabilizers. Neuropsychopharmacology 2009;34:1395-1405.
42. Rinaldi A, Vincenti S, De Vito F, Bozzoni I, Oliverio A, Presutti C, et al. Stress induces region specific alterations in microRNAs expression in mice. Behav Brain Res 2010;208:265-269.
43. Mundalil Vasu M, Anitha A, Thanseem I, Suzuki K, Yamada K, Takahashi T, et al. Serum microRNA profiles in children with autism. Mol Autism 2014;5:40.
44. Shi W, Du J, Qi Y, Liang G, Wang T, Li S, et al. Aberrant expression of serum miRNAs in schizophrenia. J Psychiatr Res 2012;46:198-204.
45. Miguel C, Albuquerque E. Drug interaction in psycho-oncology: antidepressants and antineoplastics. Pharmacology 2011;88:333-339.
46. Oved K, Morag A, Pasmanik-Chor M, Oron-Karni V, Shomron N, Rehavi M, et al. Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers. Pharmacogenomics 2012;13:1129-1139.
47. Oved K, Morag A, Pasmanik-Chor M, Rehavi M, Shomron N, Gurwitz D. Genome-wide expression profiling of human lymphoblastoid cell lines implicates integrin beta-3 in the mode of action of antidepressants. Transl Psychiatry 2013;3:e313.
48. Duric V, Banasr M, Licznerski P, Schmidt HD, Stockmeier CA, Simen AA, et al. A negative regulator of MAP kinase causes depressive behavior. Nat Med 2010;16:1328-1332.
49. Karege F, Perroud N, Burkhardt S, Fernandez R, Ballmann E, La Harpe R, et al. Protein levels of β-catenin and activation state of glycogen synthase kinase-3β in major depression. A study with postmortem prefrontal cortex. J Affect Disord 2012;136:185-188.
50. Liu R, Dang W, Jianting M, Su C, Wang H, Chen Y, et al. Citalopram alleviates chronic stress induced depression-like behaviors in rats by activating GSK3β signaling in dorsal hippocampus. Brain Res 2012; 1467:10-17.
51. Lau T, Horschitz S, Berger S, Bartsch D, Schloss P. Antidepressant-induced internalization of the serotonin transporter in serotonergic neurons. FASEB J 2008;22:1702-1714.
52. Bonnin A, Zhang L, Blakely RD, Levitt P. The SSRI citalopram affects fetal thalamic axon responsiveness to netrin-1 in vitro independently of SERT antagonism. Neuropsychopharmacology 2012;37:1879-1884.